MATTAWAN, July 23, 2007: As part of a series of planned expansions, MPI Research announced the immediate availability of additional toxicology capacity today.  Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate’s introduction to humans.

Completed July 20th, the 79,000 square foot toxicology expansion project includes the addition of 84 state-of-the-art animal rooms, new surgical suites and accommodations for specialized infusion work. The project is part of a multi-phased expansion plan fueled by the growing research and development needs of the pharmaceutical and biotechnology industries.  In 2006, the company completed toxicology expansion projects totaling $65 million, including 95 animal rooms plus significant laboratory and office space.

“Our expansion projects are driven by our customers’ need for timely, cost effective research and development services” said Bill Parfet, Chairman and Chief Executive Officer of MPI Research.  “Our ongoing investments in capacity, service expansions and infrastructure will further assure our customers of timely study starts, quality services, and on-time reporting to keep their drug development programs moving forward.”

MPI Research, with headquarters in Mattawan, Michigan, is one of the worlds leading providers of comprehensive preclinical research and development services. More information on the company’s services can be obtained through the website at www.mpiresearch.com.


Home | News